4.7 Review

Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Rheumatology

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

Melissa Northcott et al.

Summary: This study found that ISG levels are stable over time in the majority of SLE patients and do not correlate with disease activity, although IFN high status is associated with more severe SLE. High-dose glucocorticoids can suppress ISG expression, while routine dose does not.

LUPUS SCIENCE & MEDICINE (2022)

Article Rheumatology

Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus

Ting Zhang et al.

Summary: This study found that salivary levels of anti-nuclear antibody (ANA) were higher in patients with systemic lupus erythematosus (SLE) and correlated with serum ANA titers. Furthermore, salivary IgM-ANA and IgG-ANA levels were variably correlated with clinical indicators in SLE patients, suggesting their potential as substitutes for serum ANA.

ARTHRITIS RESEARCH & THERAPY (2022)

Review Rheumatology

Update on the diagnosis and management of systemic lupus erythematosus

Antonis Fanouriakis et al.

Summary: Systemic lupus erythematosus (SLE) is characterized by clinical heterogeneity, unpredictable course and flares. Diagnosis remains clinical with limited serologic test confirmation, and newer classification criteria offer more accurate classification. Treatment goals focus on patient survival, flare prevention, organ damage prevention, and quality of life optimization. High-intensity immunosuppressive therapy followed by less intensive therapy is typically used to control disease activity in severe cases of SLE.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Article Rheumatology

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus

Lloyd Mai et al.

Summary: By measuring the levels of interferon-responsive genes, the course of disease activity and treatment outcomes in SLE patients over the next 5 years can be predicted. A high baseline IFN5 level is associated with more severe outcomes.

ARTHRITIS RESEARCH & THERAPY (2021)

Article Biochemistry & Molecular Biology

Development of a Validated Interferon Score Using NanoString Technology

Hanna Kim et al.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2018)

Article Pathology

Type I Interferons in Autoimmune Disease

Mary K. Crow et al.

Annual Review of Pathology-Mechanisms of Disease (2018)

Article Biochemistry & Molecular Biology

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients

Romain Banchereau et al.

Review Immunology

Autoantibodies in SLE: Specificities, Isotypes and Receptors

Barbara Dema et al.

ANTIBODIES (2016)

Article Rheumatology

The type I IFN signature as a biomarker of preclinical rheumatoid arthritis

Joyce Luebbers et al.

ANNALS OF THE RHEUMATIC DISEASES (2013)

Review Rheumatology

Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease

Peter M. Izmirly et al.

CURRENT OPINION IN RHEUMATOLOGY (2012)

Article Rheumatology

Systemic Sclerosis and Lupus Points in an Interferon-Mediated Continuum

Shervin Assassi et al.

ARTHRITIS AND RHEUMATISM (2010)

Review Rheumatology

The management of peripheral blood cytopenias in systemic lupus erythematosus

Alastair L. Hepburn et al.

RHEUMATOLOGY (2010)

Review Rheumatology

Potential role of IFN alpha in adult lupus

Lars Ronnblom

ARTHRITIS RESEARCH & THERAPY (2010)

Article Genetics & Heredity

Peripheral blood gene expression profiling in Sjogren's syndrome

E. S. Emamian et al.

GENES AND IMMUNITY (2009)

Article Biotechnology & Applied Microbiology

Direct multiplexed measurement of gene expression with color-coded probe pairs

Gary K. Geiss et al.

NATURE BIOTECHNOLOGY (2008)

Article Genetics & Heredity

High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus

T. B. Niewold et al.

GENES AND IMMUNITY (2007)

Article Genetics & Heredity

A subtype of multiple sclerosis defined by an activated immune defense program

L. G. M. van Baarsen et al.

GENES AND IMMUNITY (2006)

Article Rheumatology

Type I interferon correlates with serological and clinical manifestations of SLE

MC Dall'Era et al.

ANNALS OF THE RHEUMATIC DISEASES (2005)

Review Medicine, General & Internal

Sjogren's syndrome

RI Fox

LANCET (2005)

Article Clinical Neurology

Interferon-α/β-mediated innate immune mechanisms in dermatomyositis

SA Greenberg et al.

ANNALS OF NEUROLOGY (2005)

Article Immunology

Anti-Sm and anti-RNP antibodies

P Migliorini et al.

AUTOIMMUNITY (2005)

Review Rheumatology

Antinuclear autoantibodies in systemic lupus erythematosus

AH Sawalha et al.

CURRENT OPINION IN RHEUMATOLOGY (2004)

Review Medicine, General & Internal

Polymyositis and dermatomyositis

MC Dalakas et al.

LANCET (2003)

Article Multidisciplinary Sciences

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

J Lee et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)